Ardagh Metal Packaging S.A. Ordinary Shares (AMBP)
3.7000
+0.0700 (1.93%)
NYSE · Last Trade: Oct 13th, 8:26 PM EDT
Detailed Quote
Previous Close
3.630
Open
3.700
Bid
3.640
Ask
3.770
Day's Range
3.665 - 3.770
52 Week Range
2.500 - 4.780
Volume
1,083,729
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
0.4000 (10.81%)
1 Month Average Volume
1,307,377
Chart
About Ardagh Metal Packaging S.A. Ordinary Shares (AMBP)
Ardagh Metal Packaging S.A. is a leading global supplier of metal packaging solutions, primarily focusing on producing high-quality aluminum and steel containers for the beverage and food industries. The company is dedicated to sustainability and innovation, employing advanced manufacturing techniques to create lightweight, recyclable packaging that meets the evolving needs of consumers and brands. Through its extensive network of production facilities, Ardagh serves a wide range of clients, enabling them to enhance their product offerings and reduce their environmental impact while ensuring the safety and quality of their packaged goods. Read More
New York, NY – October 13, 2025 – Century Aluminum Company (NASDAQ: CENX) has captured significant attention in the financial markets, with its stock recently hitting a formidable 52-week high. This impressive surge reflects a confluence of strong tailwinds in the global aluminum market and strategic, forward-looking initiatives undertaken by the company.
The session on Thursday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
AMBP stock results show that Ardagh Metal Packaging beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Amazon, which hit another high, surpassing the $200 level on Friday.
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met.
